MTOR AUTOPHAGY

SESSION CHAIR: Judith A. Potashkin, Ph.D.—Rosalind Franklin University of Medicine and Science

Wilma van de Berg, Ph.D.-VU University Medical Center Changes in mTOR signaling in the Parkinsonian brain 3:45 p.m.

Julia Fuchs, M.D., Ph.D.-CIRB/INSERM U0150/Collége de France 4:15 p.m.

Engrailed 1, mitochondrial function, oxidative stress and autophagy in

dopamine neurons

4:45 p.m Discussion

5:00 p.m. Closing remarks

DOWNLOAD THE GRAND CHALLENGES APP

Want all of the meeting details at your fingertips? Download the free Grand Challenges in Parkinson's Disease app by installing Whova from Google Play or the App Store. Once downloaded, search "Grand Challenges in Parkinson's Disease" and select "join." When prompted for an event code, please use **GCPD2017**.

THANK YOU TO OUR SPONSORS!

Session sponsors





Lunch sponsor





Supporting sponsors

















GRAND CHALLENGES IN PARKINSON'S DISEASE

THE ROLE OF ENERGY METABOLISM | VAN ANDEL RESEARCH INSTITUTE

September 27-28, 2017



www.grandchallengesinpd.org

4:05 p.m. Wednesday, September 27, 2017 Abstract selected talk Anumantha Kanthasamy, Ph.D.-Iowa State University 7:00 a.m. Continental breakfast Novel mitochondria-targeted drug induces pro-survival signaling and increases respiration to promote mitochondrial biogenesis WELCOME AND JAY VAN ANDEL AWARD ADDRESS against dopaminergic neurotoxicity 8:00 a.m. Peter Jones, Ph.D., D.Sc.-Van Andel Research Institute 4:20 p.m. Discussion Welcome and opening remarks 4:45 p.m. Poster session 8:05 a.m. Patrik Brundin, M.D., Ph.D.-Van Andel Research Institute Introduction of honoree I. William Langston, M.D. 7:00 p.m. Scientific networking dinner Please note, attendees must have signed up during registration 8:10 a.m. J. William Langston, M.D.-Parkinson's Institute and Clinical Center Jay Van Andel Award for Outstanding Achievement in Parkinson's Thursday, September 28, 2017 Disease Research The MPTP story: How it changed Parkinson's disease research 7:00 a.m. Continental breakfast DOPAMINE NEURONS/ENERGY REQUIREMENTS/CALCIUM HANDLING 9:10 a.m. Discussion SESSION CHAIR: Michele Tagliati, M.D.—Cedars-Sinai Medical Center 9:25 a.m. Break 8:00 a.m. Paul Schumacker, Ph.D.-Feinberg School of Medicine, Northwestern University DIABETES AND INFLAMMATION Calcium entry and mitrochondrial oxidant stress in Parkinson's disease SESSION CHAIR: Timothy Greenamyre, M.D., Ph.D.—Pittsburgh Institute for Louis-Eric Trudeau, Ph.D.-Université de Montréal 8:30 a.m. **Neurodegenerative Diseases** The influence of bioenergenetics and axonal arborization on dopamine neuron 9:40 a.m. Michele Tagliati, M.D.-Cedars-Sinai Medical Center vulnerability in Parkinson's disease Impaired glucose tolerance in Parkinson's disease 9:00 a.m. Discussion 10:10 a.m. Judith A. Potashkin, Ph.D.-Rosalind Franklin University of Medicine and PGC1A SESSION CHAIR: Wilma van de Berg, Ph.D.—VU University Medical Center Diabetes and inflammation in Parkinson's disease 9:15 a.m. Ted Dawson, M.D., Ph.D.-Johns Hopkins University 10:40 a.m. Abstract selected talk PGC-1-alpha dysregulation in Parkinson's disease Maria Elizabeth de Sousa, Ph.D.-Emory University 9:45 a.m. Clemens Scherzer, M.D.-Harvard Medical School Western diet and psychological stress are risk factors for insulin resistance A genome-driven view: PGC-1-alpha and more in the brain and periphery. The role of soluble tumor necrosis factor 10:15 a.m. Discussion 10:55 a.m. Discussion 10:30 a.m. Break PHYSICAL EXERCISE IN PD AND ANIMAL MODELS **MITOPHAGY** SESSION CHAIR: Darren Moore, Ph.D.—Van Andel Research Institute SESSION CHAIR: Shalini Padmanabhan, Ph.D.—The Michael J. Fox Foundation for 11:10 a.m. Michael Jakowec, Ph.D.-University of Southern California Parkinson's Research Effects of exercise in animal models of Parkinson's disease 10:45 a.m. Xinnan Wang, M.D., Ph.D.-Stanford University J. Eric Ahlskog, Ph.D., M.D.-Mayo Clinic 11:40 a.m. Changes in Miro are coupled to perturbed mitophagy in Parkinson's disease Vigorous exercise as a possible neuroprotective strategy in Parkinson's disease Charleen T. Chu, M.D., Ph.D.-University of Pittsburgh Medical School 11:15 a.m. 12:10 p.m. Discussion Mitochondrial mechanisms in Parkinson's disease: Mitophagy and beyond 12:25 p.m. Lunch 11:45 a.m. Discussion ANTI-DIABETIC AGENTS/MITOCHONDRIAL ENHANCERS 12:00 p.m. Lunch SESSION CHAIR: Patrik Brundin, M.D., Ph.D.—Van Andel Research Institute 1:15 p.m. Shalini Padmanabhan, Ph.D.-The Michael J. Fox Foundation for Parkinson's Afternoon opening remarks 1:30 p.m. Mitochondria as a target for developing PD therapeutics and biomarkers 1:35 p.m. Tom Foltynie, B.Sc., MBBS, MRCP, Ph.D.-University College London Exendin-4 treatment in Parkinson's disease 1:30 p.m. Report from Rallying to the Challenge MITOCHONDRIAL BIOENERGETICS/OX STRESS 2:05 p.m. Mark Mattson, Ph.D.-National Institute on Aging SESSION CHAIR: Richard Wyse, Ph.D.—The Cure Parkinson's Trust Tapping adaptive mitochondrial stress response pathways for neuroprotection 2:00 p.m. Anatoly Starkov, Ph.D.-Weill Cornell Medical College 2:35 p.m. Discussion Nrf2 signaling and oxidative stress in Parkinson's disease 2:50 p.m. Break 2:30 p.m. Ann N. Murphy, Ph.D.-University of California, San Diego MITOCHONDRIAL DYSFUNCTION The mitochondrial pyruvate carrier as a therapeutic target in SESSION CHAIR: Xinnan Wang, Ph.D.—Stanford University neurodegenerative disease Abstract selected talk 3:05 p.m. Timothy Greenamyre, M.D., Ph.D.-Pittsburgh Institute for 3:00 p.m. Sonia George, Ph.D.- Van Andel Research Institute Neurodegenerative Diseases

3:15 p.m.

3:30 p.m.

Discussion

Break

Mitochondrial pyruvate carrier regulates cellular metabolism and inflammation in experimental models of Parkinson's disease

3:35 p.m. Flint Beal, M.D.-Weill Cornell Medical College Mitochondrial deficits in Parkinson's disease

Mitochondria and LRRK2 in idiopathic PD